LifeSci Acquisition II Corp.
LSAQ
NASDAQ Global Select9.01
USD
-0.18
- -
LifeSci Acquisition II Corp.
LSAQ
(NASDAQ Global Select)
Recent
price
9.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- LifeSci Acquisition II Corp. (NASDAQ:LSAQ) is a blank check company, or special purpose acquisition company (SPAC), whose principal business activity involves effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on the biopharma, medical technology, digital health, and healthcare services sectors in North America or Europe. The company maintains no significant operations of its own and holds the majority of its funds raised from its initial public offering in trust for use in a potential transaction. Founded in 2020 and headquartered in New York, LifeSci Acquisition II Corp. operates as a publicly listed entity sponsored by affiliates of LifeSci Advisors and LifeSci Capital, with Andrew McDonald serving as CEO. In October 2021, the company completed a definitive business combination with Science 37, Inc., a clinical trial platform provider, resulting in the combined entity trading under a new ticker symbol and netting approximately $235 million in gross proceeds, including $80 million from the SPAC trust and a $200 million PIPE investment; the post-merger company assumed Science 37's operations as an operating system for agile clinical trials. As of late 2025, LSAQ shares continue to trade, though the ticker has been flagged for potential delisting amid ongoing market dynamics for legacy SPACs.
Why Is Science 37 (SNCE) Stock Up 9% Today?
Science 37 Holdings, Inc. (SNCE) CEO David Coman on Q4 2021 Results - Earnings Call Transcript
Science 37: Pioneering Decentralized Clinical Trials
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
U.S. IPO Weekly Recap: Breast Cancer Biotech Pops 158% In A 6-IPO Week
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering